Spirox has announced it has secured $18.5 million in series B funding.
Spirox, based in Menlo Park, Calif., develops minimally invasive technologies to treat nasal obstruction.
The financing round was led by Venrock and Aisling Capital. Existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participated.
Spirox indicated the funding will go toward completing development of a minimally invasive system to be used by ENT physicians and plastic surgeons to treat nasal obstruction, seeking U.S. marketing authorization and initiating product commercialization.
